athenahealth's (ATHN) strong product portfolio is likely to expand its customer base in the coming quarters.
Market seems to be upbeat about Haemonetics' (HAE) newly-launched platform, NexSys Plasma Collection System (PCS).
Ahead of Walgreens Boots' (WBA) second-quarter fiscal 2018 results, we are upbeat about the stock's strength in Retail Pharmacy USA division and prescription growth on account of Medicare Part D.
Positive tidings on the regulatory front have been lending Edwards Lifesciences (EW) a competitive edge in MedTech.
Neogen (NEOG) witnesses year-over-year revenue increase in both the segments in Q3.
ResMed (RMD) boosts investor confidence on strength in Software-as-a-Service businesses as well as new mask products and devices.
Edwards' (EW) near-term product pipeline looks quite encouraging.
Orthofix's (OFIX) latest receipt of FDA approval expected to enhance the Extremity Fixation portfolio.
IDEXX (IDXX) might gain from the commercial launch of Catalyst SDMA Test in North America. As a result, its point-of-care customers can add SDMA as an essential element to the routine chemistry panel.
Even after the NxThera purchase deal culminates, it is not likely to add stimulus to Boston Scientific's (BSX) adjusted earnings per share through 2020 and prove to be accretive only later.
Baxter (BAX) steadily focuses on improving its Advanced Surgery business.
Boston Scientific (BSX) forges ahead with initiatives to strengthen its hold in the high-potential EP market.
Wright Medical (WMGI) is focusing on product innovation through research and development. Also, the company is focusing on strategic acquisition and divestitures.
Medtronic (MDT) is consistently trying to improve its Cardiac Rhythm and Heart Failure division.
Varian Medical's (VAR) ProBeam system is a leading platform in advanced cancer-care technologies.
Phibro Animal Health (PAHC) continues to boost investor confidence on the back of sturdy segmental performances.
Edwards (EW) forges ahead with initiatives to strengthen the Critical Care business.
Recent buyouts and positive regulatory tidings boost investors' confidence on Baxter International (BAX).
Abbott (ABT) is is leaving no stone unturned to drive its Structural Heart business.